Neuroprotective effects of the mood stabilizer lamotrigine against glutamate excitotoxicity: Roles of chromatin remodelling and Bcl-2 induction

International Journal of Neuropsychopharmacology

Volumn 16, Issue 3, 2013, Pages 607-620

  Leng, Yan ^a   Fessler, Emily Bame ^a   Chuang, De Maw ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Bcl 2; glutamate; histone deacetylase; lamotrigine; neuroprotection

Indexed keywords

GLUTAMIC ACID; HISTONE ACETYLTRANSFERASE; HISTONE H3; HISTONE H4; LAMOTRIGINE; LITHIUM; MESSENGER RNA; PROTEIN BCL 2; SHORT HAIRPIN RNA; VALPROIC ACID;

ANIMAL CELL; ARTICLE; B CELL LYMPHOMA; CELL ASSAY; CELL PROTECTION; CELL STRUCTURE; CELL VIABILITY; CHROMATIN CONDENSATION; CHROMATIN IMMUNOPRECIPITATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME INHIBITION; EXCITOTOXICITY; GENE SILENCING; GRANULE CELL; HISTONE ACETYLATION; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; NERVE CELL CULTURE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING;

AFFECT; ANIMALS; ANTIMANIC AGENTS; CELL SURVIVAL; CELLS, CULTURED; CEREBELLUM; CHROMATIN ASSEMBLY AND DISASSEMBLY; GLUTAMIC ACID; NEUROPROTECTIVE AGENTS; PROTO-ONCOGENE PROTEINS C-BCL-2; RATS; RATS, SPRAGUE-DAWLEY; TRIAZINES;

EID: 84874582496     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145712000429     Document Type: Article

References (69)

1. Bowden CL (2002). Lamotrigine in the treatment of bipolar disorder. Expert Opinion on Pharmacotherapy 3, 1513-1519. (Pubitemid 35174883)
2. Bravo JA, Diaz-Veliz G, Mora S, Ulloa JL, et al. (2009). Desipramine prevents stress-induced changes in depressive-like behavior and hippocampal markers of neuroprotection. Behavioural Pharmacology 20, 273-285.
3. Calabrese JR, Bowden CL, Sachs GS, Ascher JA, et al. (1999). A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. Journal of Clinical Psychiatry 60, 79-88. (Pubitemid 29104383)
4. Calabresi P, Picconi B, Saulle E, Centonze D, et al. (2000). Is pharmacological neuroprotection dependent on reduced glutamate release? Stroke 31, 766-772; discussion 773.
5. Chalecka-Franaszek E, Chuang DM (1999). Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons. Proceedings of the National Academy of Sciences USA 96, 8745-8750. (Pubitemid 29354862)
6. Chang YC, Rapoport SI, Rao JS (2009). Chronic administration of mood stabilizers upregulates BDNF and bcl-2 expression levels in rat frontal cortex. Neurochemical Research 34, 536-541.
7. Chen G, Zeng WZ, Yuan PX, Huang LD, et al. (1999). The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS. Journal of Neurochemistry 72, 879-882. (Pubitemid 29055256)
8. Chen RW, Chuang DM (1999). Long term lithium treatment suppresses p53 and Bax expression but increases Bcl-2 expression. A prominent role in neuroprotection against excitotoxicity. Journal of Biological Chemistry 274, 6039-6042.
9. Chiu CT, Chuang DM (2010). Molecular actions and therapeutic potential of lithium in preclinical and clinical studies of CNS disorders. Pharmacology and Therapeutics 128, 281-304.
10. Chiu CT, Liu G, Leeds P, Chuang DM (2011). Combined treatment with the mood stabilizers lithium and valproate produces multiple beneficial effects in transgenic mouse models of Huntington's disease. Neuropsychopharmacology 36, 2406-2421.
11. Chuang DM, Leng Y, Marinova Z, Kim HJ, et al. (2009). Multiple roles of HDAC inhibition in neurodegenerative conditions. Trends in Neurosciences 32, 591-601.
12. Cimmino A, Calin GA, Fabbri M, Iorio MV, et al. (2005). miR-15 and miR-16 induce apoptosis by targeting BCL2. Proceedings of the National Academy of Sciences USA 102, 13944-13949. (Pubitemid 41377683)
13. Connop BP, Boegman RJ, Beninger RJ, Jhamandas K (1997). Malonate-induced degeneration of basal forebrain cholinergic neurons : attenuation by lamotrigine, MK-801, and 7-nitroindazole. Journal of Neurochemistry 68, 1191-1199. (Pubitemid 27086225)
14. Creson TK, Yuan P, Manji HK, Chen G (2009). Evidence for involvement of ERK, PI3K, and RSK in induction of Bcl-2 by valproate. Journal of Molecular Neuroscience 37, 123-134.
15. de Smaele E, Di Marcotullio L, Moretti M, Pelloni M, et al. (2011). Identification and characterization of KCASH2 and KCASH3, 2 novel Cullin3 adaptors suppressing histone deacetylase and Hedgehog activity in medulloblastoma. Neoplasia 13, 374-385.
16. Doble A (1999). The role of excitotoxicity in neurodegenerative disease : implications for therapy. Pharmacology and Therapeutics 81, 163-221. (Pubitemid 29094735)
17. Faught E, Morris G, Jacobson M, French J, et al. (1999). Adding lamotrigine to valproate: incidence of rash and other adverse effects. Postmarketing Antiepileptic Drug Survey (PADS) Group. Epilepsia 40, 1135-1140. (Pubitemid 29372630)
18. Gidal BE, Sheth R, Parnell J, Maloney K, et al. (2003). Evaluation of VPA dose and concentration effects on lamotrigine pharmacokinetics : implications for conversion to lamotrigine monotherapy. Epilepsy Research 57, 85-93. (Pubitemid 38167725)
19. Hait NC, Allegood J, Maceyka M, Strub GM, et al. (2009). Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate. Science 325, 1254-1257.
20. Halonen T, Nissinen J, Pitkänen A (2001). Effect of lamotrigine treatment on status epilepticus-induced neuronal damage and memory impairment in rat. Epilepsy Research 46, 205-223. (Pubitemid 32772811)
21. Hunsberger JG, Austin DR, Chen G, Manji HK (2009). MicroRNAs in mental health : from biological underpinnings to potential therapies. Neuro Molecular Medicine 11, 173-182.
22. Johannessen SI, Battino D, Berry DJ, Bialer M, et al. (2003). Therapeutic drug monitoring of the newer antiepileptic drugs. Therapeutic Drug Monitoring 25, 347-363. (Pubitemid 36638181)
23. Kanai H, Sawa A, Chen RW, Leeds P, et al. (2004). Valproic acid inhibits histone deacetylase activity and suppresses excitotoxicity-induced GAPDH nuclear accumulation and apoptotic death in neurons. Pharmacogenomics Journal 4, 336-344. (Pubitemid 39341573)
24. Kim YJ, Ko HH, Han ES, Lee CS (2007). Lamotrigine inhibition of rotenone-or 1-methyl-4-phenylpyridiniuminduced mitochondrial damage and cell death. Brain Research Bulletin 71, 633-640. (Pubitemid 46209530)
25. Klein PS, Melton DA (1996). A molecular mechanism for the effect of lithium on development. Proceedings of the National Academy of Sciences USA 93, 8455-8459. (Pubitemid 26269579)
26. Kosten TA, Galloway MP, Duman RS, Russell DS, et al. (2008). Repeated unpredictable stress and antidepressants differentially regulate expression of the bcl-2 family of apoptotic genes in rat cortical, hippocampal, and limbic brain structures. Neuropsychopharmacology 33, 1545-1558. (Pubitemid 351684697)
27. Lagrue E, Chalon S, Bodard S, Saliba E, et al. (2007). Lamotrigine is neuroprotective in the energy deficiency model of MPTP intoxicated mice. Pediatric Research 62, 14-19. (Pubitemid 46985843)
28. Lee AL, Ogle WO, Sapolsky RM (2002). Stress and depression: possible links to neuron death in the hippocampus. Bipolar Disorders 4, 117-128. (Pubitemid 34411274)
29. Lee CY, Fu WM, Chen CC, Su MJ, et al. (2008). Lamotrigine inhibits postsynaptic AMPA receptor and glutamate release in the dentate gyrus. Epilepsia 49, 888-897.
30. Lees G, Leach MJ (1993). Studies on the mechanism of action of the novel anticonvulsant lamotrigine (Lamictal) using primary neurological cultures from rat cortex. Brain Research 612, 190-199. (Pubitemid 23167279)
31. Leng Y, Chuang DM (2006). Endogenous alpha-synuclein is induced by valproic acid through histone deacetylase inhibition and participates in neuroprotection against glutamate-induced excitotoxicity. Journal of Neuroscience 26, 7502-7512. (Pubitemid 44315219)
32. Leng Y, Liang MH, Ren M, Marinova Z, et al. (2008). Synergistic neuroprotective effects of lithium and valproic acid or other histone deacetylase inhibitors in neurons: roles of glycogen synthase kinase-3 inhibition. Journal of Neuroscience 28, 2576-2588. (Pubitemid 351348211)
33. Lien R, Flaisher-Grinberg S, Cleary C, Hejny M, et al. (2008). Behavioral effects of Bcl-2 deficiency: implications for affective disorders. Pharmacological Reports 60, 490-498.
34. Liu X, Zhu XZ (1999). Roles of p53, c-Myc, Bcl-2, Bax and caspases in glutamate-induced neuronal apoptosis and the possible neuroprotective mechanism of basic fibroblast growth factor. Molecular Brain Research 71, 210-216. (Pubitemid 29492965)
35. Lyoo IK, Dager SR, Kim JE, Yoon SJ, et al. (2010). Lithium-induced gray matter volume increase as a neural correlate of treatment response in bipolar disorder : A longitudinal brain imaging study. Neuropsychopharmacology 35, 1743-1750.
36. Machado-Vieira R, Pivovarova NB, Stanika RI, Yuan P, et al. (2011). The Bcl-2 gene polymorphism rs956572AA increases inositol 1,4,5-trisphosphate receptor-mediated endoplasmic reticulum calcium release in subjects with bipolar disorder. Biological Psychiatry 69, 344-352.
37. Malkesman O, Austin DR, Tragon T, Henter ID, et al. (2011). Targeting the BH3-interacting domain death agonist to develop mechanistically unique antidepressants. Molecular Psychiatry. Published online : 5 July 2011. doi :10.1038/mp.2011.77.
38. Manji HK, Moore GJ, Chen G (2000). Clinical and preclinical evidence for the neurotrophic effects of mood stabilizers : implications for the pathophysiology and treatment of manic-depressive illness. Biological Psychiatry 48, 740-754.
39. Mantegazza M, Curia G, Biagini G, Ragsdale DS, et al. (2010). Voltage-gated sodium channels as therapeutic targets in epilepsy and other neurological disorders. Lancet Neurology 9, 413-424.
40. Marinova Z, Ren M, Wendland JR, Leng Y, et al. (2009). Valproic acid induces functional heat-shock protein 70 via Class I histone deacetylase inhibition in cortical neurons: A potential role of Sp1 acetylation. Journal of Neurochemistry 111, 976-987.
41. Monti B, Gatta V, Piretti F, Raffaelli SS, et al. (2010). Valproic acid is neuroprotective in the rotenone rat model of Parkinson's disease : involvement of alpha-synuclein. Neurotoxicity Research 17, 130-141.
42. Moore GJ, Bebchuk JM, Hasanat K, Chen G, et al. (2000a). Lithium increases N-acetyl-aspartate in the human brain : in vivo evidence in support of bcl-2's neurotrophic effects? Biological Psychiatry 48, 1-8. (Pubitemid 30407144)
43. Moore GJ, Bebchuk JM, Wilds IB, Chen G, et al. (2000b). Lithium-induced increase in human brain grey matter. Lancet 356, 1241-1242.
44. Morris RG, Lee MY, Cleanthous X, Black AB (2004). Longterm follow-up using a higher target range for lamotrigine monitoring. Therapeutic Drug Monitoring 26, 626-632. (Pubitemid 39579143)
45. Nonaka S, Hough CJ, Chuang DM (1998). Chronic lithium treatment robustly protects neurons in the central nervous system against excitotoxicity by inhibiting N-methyl-Daspartate receptor-mediated calcium influx. Proceedings of the National Academy of Sciences USA 95, 2642-2647. (Pubitemid 28145996)
46. Papazisis G, Kallaras K, Kaiki-Astara A, Pourzitaki C, et al. (2008). Neuroprotection by lamotrigine in a rat model of neonatal hypoxic-ischaemic encephalopathy. International Journal of Neuropsychopharmacology 11, 321-329. (Pubitemid 351482501)
47. Paul IA, Skolnick P (2003). Glutamate and depression: clinical and preclinical studies. Annals of the New York Academy of Sciences 1003, 250-272. (Pubitemid 38083061)
48. Phiel CJ, Zhang F, Huang EY, Guenther MG, et al. (2001). Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. Journal of Biological Chemistry 276, 36734-36741.
49. Redmond JR, Jamison KL, Bowden CL (2006). Lamotrigine combined with divalproex or lithium for bipolar disorder : A case series. CNS Spectrums 11, 915-918. (Pubitemid 46025636)
50. Roh MS, Eom TY, Zmijewska AA, De Sarno P, et al. (2005). Hypoxia activates glycogen synthase kinase-3 in mouse brain in vivo : protection by mood stabilizers and imipramine. Biological Psychiatry 57, 278-286. (Pubitemid 40187372)
51. Rohn TT, Vyas V, Hernandez-Estrada T, Nichol KE, et al. (2008). Lack of pathology in a triple transgenic mouse model of Alzheimer's disease after overexpression of the anti-apoptotic protein Bcl-2. Journal of Neuroscience 28, 3051-3059. (Pubitemid 351442294)
52. Ryves WJ, Harwood AJ (2001). Lithium inhibits glycogen synthase kinase-3 by competition for magnesium. Biochemical and Biophysical Research Communications 280, 720-725. (Pubitemid 32924489)
53. Schloesser RJ, Huang J, Klein PS, Manji HK (2008). Cellular plasticity cascades in the pathophysiology and treatment of bipolar disorder. Neuropsychopharmacology 33, 110-133. (Pubitemid 350191320)
54. Shuaib A, Mahmood RH, Wishart T, Kanthan R, et al. (1995). Neuroprotective effects of lamotrigine in global ischemia in gerbils. A histological, in vivo microdialysis and behavioral study. Brain Research 702, 199-206.
55. Sinn DI, Kim SJ, Chu K, Jung KH, et al. (2007). Valproic acid-mediated neuroprotection in intracerebral hemorrhage via histone deacetylase inhibition and transcriptional activation. Neurobiology of Disease 26, 464-472. (Pubitemid 46578295)
56. Smith SE, Meldrum BS (1995). Cerebroprotective effect of lamotrigine after focal ischemia in rats. Stroke 26, 117-122.
57. Tsai LK, Leng Y, Wang Z, Leeds P, et al. (2010). The mood stabilizers valproic acid and lithium enhance mesenchymal stem cell migration via distinct mechanisms. Neuropsychopharmacology 35, 2225-2237.
58. Uemura T, Green M, Corson TW, Perova T, et al. (2011). Bcl-2 SNP rs956572 associates with disrupted intracellular calcium homeostasis in bipolar I disorder. Bipolar Disorders 13, 41-51.
59. van der Loos ML, Mulder PG, Hartong EG, Blom MB, et al. (2009). Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: A multicenter, double-blind, placebo-controlled trial. Journal of Clinical Psychiatry 70, 223-231.
60. Vukosavic S, Stefanis L, Jackson-Lewis V, Guegan C, et al. (2000). Delaying caspase activation by Bcl-2 : A clue to disease retardation in a transgenic mouse model of amyotrophic lateral sclerosis. Journal of Neuroscience 20, 9119-9125. (Pubitemid 32042914)
61. Walden J, Hesslinger B, van Calker D, Berger M (1996). Addition of lamotrigine to valproate may enhance efficacy in the treatment of bipolar affective disorder. Pharmacopsychiatry 29, 193-195. (Pubitemid 26315671)
62. Wang SJ, Sihra TS, Gean PW (2001). Lamotrigine inhibition of glutamate release from isolated cerebrocortical nerve terminals (synaptosomes) by suppression of voltageactivated calcium channel activity. Neuroreport 12, 2255-2258. (Pubitemid 32646283)
63. Wang X, Liu P, Zhu H, Xu Y, et al. (2009). miR-34a, a microRNA up-regulated in a double transgenic mouse model of Alzheimer's disease, inhibits bcl2 translation. Brain Research Bulletin 80, 268-273.
64. Wang Z, Leng Y, Tsai LK, Leeds P, et al. (2011). Valproic acid attenuates blood-brain barrier disruption in a rat model of transient focal cerebral ischemia: The roles of HDAC and MMP-9 inhibition. Journal of Cerebral Blood Flow and Metabolism 31, 52-57.
65. Wiard RP, Dickerson MC, Beek O, Norton R, et al. (1995). Neuroprotective properties of the novel antiepileptic lamotrigine in a gerbil model of global cerebral ischemia. Stroke 26, 466-472.
66. Yuan J, Lipinski M, Degterev A (2003). Diversity in the mechanisms of neuronal cell death. Neuron 40, 401-413. (Pubitemid 37244104)
67. Zarate CA, Quiroz JA (2003). Combination treatment in bipolar disorder : A review of controlled trials. Bipolar Disorders 5, 217-225. (Pubitemid 36748484)
68. Zhou R, Yuan P, Wang Y, Hunsberger JG, et al. (2009). Evidence for selective microRNAs and their effectors as common long-term targets for the actions of mood stabilizers. Neuropsychopharmacology 34, 1395-1405.
69. Zona C, Avoli M (1997). Lamotrigine reduces voltage-gated sodium currents in rat central neurons in culture. Epilepsia 38, 522-525. (Pubitemid 27199905)